
### **CAS SciFinder**

# 全程助力医药科学研究

客户顾问: 匡金海

邮箱: jkuang@acs-i.org







### 大纲


- CAS及CAS SciFinder介绍
- 文献相关信息的获取策略
  - ▶ 文献检索方法
  - ▶ 文献结果排序、筛选和详情
  - ➤ 如何高效阅读专利文献详情(CAS PatentPak)
- 物质相关信息的获取策略
  - ▶ 常见的物质检索方法
  - ▶ 物质结果排序、筛选和详情
- 反应相关信息的获取策略
  - ▶ 反应的获取方法
  - ▶ 反应结果排序、筛选和详情
  - ➤ 如何高效获取反应详情(Synthetic Methods)
- 分析相关信息的获取 (CAS Analytical Methods)





### CAS致力于提高创新效率

CAS的数据和服务是基于对以往知识经验的回顾,对当代前沿研究的洞察,以及对未来发展趋势的前瞻



#### HINDSIGHT

Connecting past discoveries to build a better future

连接前人的发现,建设更美好的未来

#### **INSIGHT**

Revealing unseen relationships that spark ideas and speed discovery

揭示能激发想法和加速发现的,未预见的联系

#### **FORESIGHT**

Identifying trends and emerging opportunities to accelerate growth

确定加速增长的趋势和新机遇





### CAS具有最全面的学科连接内容合集

**ACTIVE PHARMA INGREDIENT** 

COSMETIC FORMULATIONS

**INFRARED DATA** 

ANALYTICAL METHODS PROTOCOLS **GLOBAL REGULATIONS** SPECTRAL DATA

STRUCTURES REACTIONS

PHARMACOLOGY / TOXICOLOGY

**PROCESSES** 

STRUCTURE-ACTIVITY-RELATIONSHIP

**PROPERTIES** 

IP CLAIMS

INGREDIENT FUNCTIONS

**DNA / RNA SEQUENCES** 

MARKUSH

DISEASES

**UVCB SUBSTANCES** 

**NMR DATA** 

**FORMULATIONS** 

**CELL LINES / TYPES** 

POLYMER PROPERTIES

MASS SPEC DATA

BIOMOLECULE ISOLATION

**TARGETS** 

AGRICULTURE FORMULATIONS

**PROTOCOLS** 

ORGANOMETALLICS / INORGANICS

BIOASSAYS

Over

50K

scientific journals and documents

Over

**250** 

million substances

Over

languages translated

patent offices worldwide



### CAS SciFinder覆盖的学科


### 一生物化学:

- ~ 农化产品管控信息、生化遗传学、发酵、免疫化学、药理学
- 看机化学各领域:
  - 氨基酸、生物分子、碳水化合物、有机金属化合物、类固醇
- 大分子化学各领域:
  - 「纤维素、木质素、造纸;涂料、墨水
  - 染料、有机颜料; 合成橡胶; 纺织品、纤维
- 一应用化学各领域:
  - 大气污染、陶瓷、精油、化妆品、化石燃料、黑色金属、合金
- ■物理、无机、分析化学各领域:
  - 表面化学、催化剂、相平衡、核现象、电化学



## CAS科学家的智力标引


comprehensive search results.















Androst-4-en-3-one, 17-hydroxy-17methyl-, (17β)-

CAS科学家利用人类智慧对公开内容进行揭示,使相关信息更容易被挖掘





### CAS内容合集--CAS SciFinder



CAS SciFinder是提供经CAS科学家人工标引内容的工具型解决方案。





### CAS解决方案与服务

**DISCOVERY** 



### CAS SciFinder Discovery Platform™

Get discoveries to market faster and optimize margins by giving researchers the information they need

INTELLECTUAL PROPERTY



### STN IP Protection Suite<sup>TM</sup>

Ensure that your intellectual property is protected and find opportunities to extend into new markets

**CUSTOM SOLUTIONS** 




### CAS Custom Services<sup>SM</sup>

Customized data, analytics and insights to maximize the value of information assets and fuel digitalization success





# CAS SciFinder登录网址 https://SciFinder.cas.org




每个用户必须注册后才能使用





### CAS SciFinder主界面







### 大纲

- CAS及CAS SciFinder介绍
- 文献相关信息的获取策略
  - ▶ 文献检索方法
  - ▶ 文献结果排序、筛选和详情
  - ➤ 如何高效阅读专利文献详情(CAS PatentPak)
- 物质相关信息的获取策略
  - ▶ 常见的物质检索方法
  - ▶ 物质结果排序、筛选和详情
- 反应相关信息的获取策略
  - > 反应的获取方法
  - ▶ 反应结果排序、筛选和详情
  - ➤ 如何高效获取反应详情 (Synthetic Methods)
- 分析相关信息的获取 (CAS Analytical Methods)





### CAS SciFinder检索--文献检索

- 文献检索方法
  - = 主题检索
  - 作者名检索
  - 机构名检索
  - 文献标识符检索
  - 期刊名称和专利信息(公开号,申请号等)
  - 从物质,反应获得文献
- 检索策略推荐
  - 关注某特定领域的文献: 主题检索
  - 关注物质有关的文献: 先获得物质, 再获得文献
  - 关注某科研人员的文献: 作者名检索
  - 关注某机构科研进展: 机构名检索







### 文献检索--主题

主题检索: 老药新用治疗COVID-19

检索式: drug repurposing in COVID-19







### 主题检索的候选项

Select All Deselect All			
0 of 9 Research Topic Candidates Selected			
80 references were found containing "drug repurposing in COVID-19" as entered.	80		
955 references were found containing the two concepts 'drug repurposing" and "COVID 19' closely associated with one another.	955		
1633 references were found where the two concepts "drug repurposing" and "COVID 19" were present anywhere in the reference.	1633		
25118 references were found containing at least two of the concepts "drug", "repurposing", "COVID" or "19" closely associated with one another.	25118		
282603 references were found where at least two of the concepts "drug", "repurposing", "COVID" or "19" were present anywhere in the reference.	282603		
8049 references were found containing the concept "drug repurposing".	8049		
9339226 references were found containing either the concept "drug" or the concept "repurposing".	9339226		
116406 references were found containing the concept "COVID 19".	116406		
☐ 1980199 references were found containing either the concept "COVID" or the concept "19".	1980199		
Get References			
derredenies			

"Concepts"表示对主题词做了同义词的扩展;


"Closely associated with one another"表示同时出现在一个句子中;

"were present anywhere in the reference"表示同时出现在一篇文献中;





# 文献结果集的排序--Citing Reference




Citing Reference: 帮助找到最重要的文献





# 文献结果集的筛选--Analyze

#### 本领域研究人员



本领域研究机构、 合作伙伴、竞争对手

Analyze	Refine	Categorize
Analyze	bv: 🕝	
	y-Organizat	tion 🗸
USA		23
National of Health	Institutes n, USA	11
Kannur l India	Jniversity,	6
Universit Michigan		6
Amity Ur India	niversity,	5
	Academy ( , Peop Rep	
Cornell USA	Jniversity,	5

期刊

Analyze	Refine	Categorize
Analyze	bv: 🕡	
Journal 1		~
ChemRxi	iv	148
bioRxiv		95
Journal of Biomoleo Structure Dynamic	cular e and	58
Journal of biomoleo structure dynamics	cular e &	55
medRxiv		44
Europea pharmac	n journal o cology	of 25


涉及学科领域

Analyze	Refine	Categorize		
Analyze	bv: 🕝			
CA Section Title				
Pharmac	cology	721		
Mammal Patholog				
Biochem	istry	128		
Immuno	chemistry	34		
	Education, umentatior	n 20		
Pharmac	euticals	18		
Enzymes	3	13		
	l, Algal, an liochemistr			
Biochem Methods		5		





# 文献结果集的筛选--Analyze



Index Term:

帮助用户了解涉及到的重要技术术语,并修正检索词


Analyze - Index Term	
⚠ Only 1,000 Terms are displayed.	close
3773 Items 1 Selected	Export
Sort by: Frequency ✓	f 20 🕨 🔰
Select bars to view only those references within the current answer set.	
✓ COVID-19	1022 🔺
Severe acute respiratory syndrome coronavirus 2	963
☐ Homo sapiens	611
☐ Drug repurposing	595
References not containing information for this analysis	495
Human	480
☐ Antiviral agents	452
□ Coronavirus Infections	272
☐ Pneumonia, Viral	268
Pandemics	266
Apply	Cancel


选择感兴趣的内容,点击Apply





## 文献结果集的筛选--Refine





Refine: 帮助用户迅速获得需要的文献






# 文献结果集的筛选--Categorize

学科领域 主分类 学科领域 副分类

**Index Term** 

选中的Index Term




Categorize学科分类功能,基于Index Term,根据大学科方向对文献进行自动分类。





### 药剂学文献信息检索策略

- •Step 1: 由结构信息获取文献
- •Step 2: 通过Catagorize系统分类功能筛选药剂学文献








### 药代动力学文献信息检索策略

- •Step 1: 由结构信息获取文献
- •Step 2: 通过Catagorize系统分类功能筛选药代动力学文献








### 药理学文献信息检索策略

Step 1: 由结构信息获取文献

Step 2: 选择analyze, CA section title, Pharmacology, 点击keep analysis








### 药理学文献信息检索策略

获得体外实验文献的检索方法


Step 3: 选择refine, research topic, 输入vitro







## 文献结果集的保存



Save: 保存在服务器上, 方便以后登陆查看,每 次可存1万条记录。

Export: 导出至本地电脑。

Print: 打印成PDF格式





# 文献结果详情--题录、摘要、索引

#### 2. Potential Therapeutic Options for COVID-19

By: Zheng, Xiaoqin; Li, Lanjuan

A review. The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compd. libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.

#### Indexing

Pharmacology (Section1-0)

Section cross-reference(s): 14

#### Concepts

■ 重要概念

Anticoronaviral agents

COVID-19 Drug screening

Severe acute respiratory syndrome

Antiviral agents
Drug repurposing

Middle East respiratory syndrome

Severe acute respiratory syndrome coronavirus 2

potential therapeutic options for COVID-19

#### **Supplementary Terms**

review SARS CoV2 coronavirus COVID19 antiviral agent

#### Substances

### - 重要物质

118-42-3 Hydroxychloroquine 3

369372-47-4 Lopinavir/ritonavir 9

1809249-37-3 Remdesivir 9

potential therapeutic options for COVID-19

Therapeutic use; Biological study; Uses

### 文献详情界面包括:

- 1. 标题
- 2. 摘要
- 3. 文献中重要的技术术语
- 4. 文献中重要的物质
- 5. 书目信息
- 6. 获得文献中的物质,反应
- 7. 参考文献
- 8. 链接原文

#### **QUICK LINKS**

0 Tags, 0 Comments

#### SOURCE

Infectious Microbes & Diseases

Volume2

Issue3

Pages89-95

Journal; General Review; Online Computer File

2020 CODEN:IMDNCO

ISSN:2641-5917 DOI:10.1097/IM9.000000000

0000033

#### COMPANY/ORGANIZATION

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National

irch Center for seases, National er for Infectious laborative enter for d Treatment of seases, The First pital versity School of






# **PatentPak**<sup>m</sup>

专利工作流程解决方案






### 越来越多的新化合物倾向于首先通过专利公布








## -专利工作流程解决方案:






-专利工作流程解决方案








# -专利工作流程解决方案







## -专利工作流程解决方案








### -专利工作流程解决方案

Always Show

Advanced Search







### 节省您最宝贵的资源——时间



- 即时获得来自世界上46家专利授权机构的逾1800万份专利PDF文件,且数量 持续增加
- 专利族涵盖了多种语言
- 通过CAS登记号获得物质在专利文献中的相关信息
- 专利研究安全保密
- 每日更新
- SciFinder检索功能中内置交互式浏览器
- 每日更新
- SciFinder检索功能中内置交互式浏览器





### 文献检索小结

- 1. 主题检索时,使用介词 in, with, of 等作为连接词
- 2. 跟据检索要求选择合适的候选项
- 3. 通过SciFinder 的Analyze/Refine功能来缩小检索的范围
- 4. 尝试将不同的Analyze/Refine功能组合起来用,会有更多的收益
- 5. 使用Categorize可以让系统来实现自动分类



### 大纲

- CAS及CAS SciFinder介绍
- 文献相关信息的获取策略
  - > 文献检索方法
  - ▶ 文献结果排序、筛选和详情
  - ▶ 如何高效阅读专利文献详情(CAS PatentPak)
- 物质相关信息的获取策略
  - > 常见的物质检索方法
  - ▶ 物质结果排序、筛选和详情
- 反应相关信息的获取策略
  - ▶ 反应的获取方法
  - ▶ 反应结果排序、筛选和详情
  - ➤ 如何高效获取反应详情 (Synthetic Methods)
- 分析相关信息的获取 (CAS Analytical Methods)





## CAS SciFinder检索--物质检索

### 物质检索方法

- = 结构式检索
- 分子式检索
- = 理化性质 (物质属性) 检索
- 物质标识符检索: 化学名称、CAS RN
- 从文献或反应结果获得

### 检索策略推荐

- 看机化合物,天然产物:结构检索
- 无机物,合金:分子式检索
- 高分子化合物: 分子式检索和结构检索

### SUBSTANCES

Chemical Structure

Markush

Molecular Formula

Property

Substance Identifier





# 物质检索--标识符检索




物质标识符包括CAS RN和化学名称,化学名称可以是通用名称、商品名、俗名。





## 物质结果集




在SciFinder中,鼠标滑过物质,即可打开物质标准菜单,获得与物质相关的所有内容






### 物质结果详情








## 物质结果详情—实验数据实验谱图






# 物质结果详情—生物活性








## 物质检索--Property Explorer







### 物质结果集的筛选--Refine









如何筛选黄酮类物质?

### 物质结果集的筛选--Refine









### 物质结果集的筛选--Refine








### 物质检索--分子式检索



含碳化合物时,则"C"在前;如有氢则紧随其

后,其它元素符号按字母顺序排在氢的后面


无机金属盐:金属离子和 阴离子间用点(.)分开








## 物质检索--结构式检索







### 物质检索--结构编辑器



重要绘制工具注释



选择可变基团



自定义R基团



重复工具



取代位置可变



锁环工具




锁原子工具






## 物质检索--精确结构检索







## 物质检索--精确结构检索




### 精确结构检索:

获得被检索结构的盐,混合物,配合物,聚合物等,被检结构不能被取代






# 物质检索--亚结构检索









### 物质检索--亚结构检索结果集



# 物质检索--亚结构检索结果集的限定




化学结构的再次限定








## 物质检索--亚结构检索结果集的限定






### 亚结构检索:

包括精确结构检索结果, 及被检索结构的修饰结构






## 物质检索--相似结构检索







## 物质检索--相似结构检索结果



### 相似结构检索:

获得片段或整体结构与被检索结构相似的结果, 母体结构可以被取代, 也可以被改变





### (19) 中华人民共和国国家知识产权局



(21) 申请号 201410122313.4

### (12) 发明专利申请



(10)申请公布号 CN 104945470 A

(22) 申请日 2014, 03, 30 (71) 申请人 浙江大学 地址 310027 浙江省杭州市西湖区浙大路 申请人 中国科学院上海药物研究所

(72) 发明人 胡永洲 李佳 刘滔 张建康 周宇波 杨波 何俏军 许磊


(74) 专利代理机构 杭州求是专利事务所有限公

代理人 张法高 赵杭丽

CO7K 5/087(2006, 01)

权利要求书3页 说明书24页 附图4页

化合物,以Carfilzonib为先导化合物,经缩 合、酸性条件下脱去 Boc 保护基、碱性条件下反 下获得。本发明是小分子短肽类蛋白酶体抑制 剂。本发明化合物且有极强的蛋白酸体抑制是 抑制剂,为癌症治疗药物的研究提供了新的思 路。本发明化合物的合成所需原料易得,路线设 计合理,反应条件温和,各步产率高,操作简便,



(43)申请公布日 2015, 09, 30

COTK 1/16(2006.01) 007K 1/06(2006, 01) A61K 38/06(2006, 01)

A61P 35/00(2006.01) A61P 35/02(2006, 01) A61P 25/28(2006, 01) A61P 37/02(2006, 01)

胡小蓓

司 33200

(51) Int. CL.

CO7K 5/083(2006.01)

### (54) 发明名称

杂环构建的三肽环氧酮类化合物及制备和应

### (57) 摘要

本发明提供一种杂环构建的三肽环氧酮类 业化生产。具有下述式 I 的结构通式:

### 具体实施方式

[0026] 本发明结合附图和实施例作进一步的说明,以下实施例仅是说明本发明,而不是 以仟何方式限制本发明。

[0027] 制备实施例 1、4-(吡嗪 -2-基氨甲酰基) 哌啶 -1-甲酸叔丁酯 (1a,1b)

将 1- (叔丁氧羰基) 哌啶 -4- 甲酸 (2.75g,12mmol) 置于 50mL 三颈瓶中, N。保护下加 入 25mL 无水 CH<sub>2</sub>C1<sub>2</sub>,然后缓缓滴入吡啶(2.5mL,30mmo1)和二氯亚砜(1.1mL,14mmo1),该 反应液置于室温反应半小时。随后,2-氨基吡嗪(0.95g,10mmo1)和三乙胺(5.7mL,40mmo1) 溶于 15mL CH<sub>2</sub>Cl<sub>2</sub>后缓缓滴入上述反应液,室温反应 6 小时。反应液加 30mL 饱和食盐水稀 释,分出有机层,水层 CH<sub>2</sub>Cl<sub>3</sub>提取(15mL×3),合并有机层,无水硫酸钠干燥后减压除去溶 剂,柱层析分离得白色固体 2.3g,收率 74%。m.p.: 134-136℃; ¹H NMR (500MHz, CDC1。):  $\delta = 9.55$  (s, 1H, pyrazine-H), 8.35 (d, 1H, J=2.0Hz, pyrazine-H), 8.23 (s, 1H, pyrazine-H), 7.97 (s. 1H, NH), 4.20 (m. 2H, CH<sub>2</sub>), 2.81 (m. 2H, CH<sub>2</sub>), 2.48 (m. 1H, CH), 1.93 (d, 2H, J=12.5Hz, CH<sub>2</sub>), 1.76 (m, 2H, CH<sub>2</sub>), 1.47 (s, 9H, CH<sub>3</sub>) ppm; ESI-MS:  $m/z = 307[M+H]^{+}$ .

[0028] 制备实施例 2、4-(吡嗪 -2- 酰基) 哌嗪 -1- 甲酸叔丁酯(1c,1d)

吡嗪 -2- 羧酸(1.5g,12mmo1) 置于 50ml 反应瓶中,加入 35mL 无水 CH,Cl。溶解,随即 加入 1- 羟基苯并三氮唑(1.6g,12mmo1)和 N-(3-二甲氨基丙基)-N'-乙基碳二亚胺盐酸 盐(3.5g,18mmo1),室温反应半小时。随后,哌嗪-1-甲酸叔丁酯(1.9g,10mmo1)加入反应 液中,室温反应3小时。反应液加入30mL饱和碳酸氢钠水溶液稀释,分出有机层,饱和食盐

### 具体物质[Specific Substance]:

以具体化学结构陈述的特定物质,会被分配CAS RN





预测性物质[Prophetic Substance]:

- 使用Markush结构陈述的预测物质,一个 Markush可以陈述上百或上千个化学物质
- 被Markush结构包含,但未被实施或呈现 在表格、权利要求书或说明书中的结构, 不会被CAS分配CAS Registry Number
- Markush检索,能检索到通过结构检索检 不到的专利

CN 104945470 A

### 权 利 要 求 书

1/3 页

1. 一种杂环构建的三肽环氧酮类化合物,具有下述结构通式 I:

$$R_7 \sim_{B_2} B \sim_{B_1} \left( \begin{array}{c} R_1 & R_4 & 0 & R_3 \\ A & N & 1 & N & N \\ R_2 & R_5 & 0 & R_6 \end{array} \right)$$

其中:

 $R_1$ ,  $R_2$ ,  $R_3$  各自独立选自 H、 $C_{1-6}$  烷基 -D、卤代的  $C_{1-6}$  烷基 -D、 $C_{1-6}$  羟基烷基、 $C_{1-6}$  巯基烷基、 $C_{1-6}$  烷氧基烷基、芳基、芳烷基、杂芳基或杂芳烷基 ;其中 :D 为  $N(R_a)$   $(R_b)$  或缺失, $R_a$ , $R_b$  各自独立选自 H、OH、 $C_{1-6}$  烷基、卤代的  $C_{1-6}$  烷基或 N 末端保护基;

 $R_4$ ,  $R_5$  各自独立选自 H、OH、 $C_{1-6}$  烷基、卤代的  $C_{1-6}$  烷基或芳烷基;

 $R_6$  选自 H,  $C_{1-6}$  烷基, 卤代的  $C_{1-6}$  烷基,  $C_{1-6}$  羟基烷基,  $C_{1-6}$  烷氧基, 卤代的  $C_{1-6}$  烷氧基, C(0) 0- $C_{1-6}$  烷基, C(0) NH- $C_{1-6}$  烷基, 芳烷基;

X 为 0、S、NH、N-C<sub>1-6</sub> 烷基或 N- 卤代的 C<sub>1-6</sub> 烷基;


其中 R 选自 H、C1-6 烷基或卤代的 C1-6 烷基;

环 A 选自 5 ~ 7 元的饱和脂肪杂环、不饱和杂环、或者有取代的 5 ~ 7 元的饱和脂肪杂环、不饱和杂环,所述的杂环包含 0 ~ 3 个选自 0 、N 和 S 的杂原子并任选地被  $R_8$ 、 $R_9$  和  $B_1$  基团取代:

 $R_8$ ,  $R_9$  分别独立选自 H、OH,  $C_{1-6}$  烷基, $C_{1-6}$  烷氧基, $C_{1-6}$  羟基烷基, $C_{1-6}$  巯基烷基, $C_{1-6}$  烷基 -D,芳基,杂环芳基,环烷基和杂环基,这些基团可以被卤素、硝基、氨基、CN、 $C_{1-6}$  烷基、卤代的  $C_{1-6}$  烷基,或卤代的  $C_{1-6}$  烷基基或卤代的  $C_{1-6}$  烷氧基取代,每个基团可与一个或多个芳基或杂环








Explore ▼	Saved Searches ▼		SciPlanner
⚠ Explore Substances resulted in 0 substances Return			
Chemical Structure substructure with limiters > substances (0)			
SUBSTANCES			
Analyze Refine			
Analyze by: No substances available			

Substance检索结果为0!







为了尽可能全面地获得公开的结构信息,需要同时进行Substance和Markush结构检索





## 物质检索小结

- 1. 选择合适的检索方式
- 2. 利用结构绘制工具合理扩大结构检索范围: R基团、可变基团、可变位置取代等
- 3. 利用结构绘制工具适当限定检索结构:环锁工具、原子锁工具、EZ构型限定等
- 4. 正确理解Exact、Substructure、Similarity检索结果集的意义和范围
- ○. 充分利用物质筛选项准确定位目标物质:Reaction Role、Reference Role等
- 6. 利用CAS Markush检索尽可能全面的获得结构的公开信息



### 大纲

- CAS及CAS SciFinder介绍
- 文献相关信息的获取策略
  - > 文献检索方法
  - ▶ 文献结果排序、筛选和详情
  - ▶ 如何高效阅读专利文献详情(CAS PatentPak)
- 物质相关信息的获取策略
  - ▶ 常见的物质检索方法
  - ▶ 物质结果排序、筛选和详情
- 反应相关信息的获取策略
  - ▶ 反应的获取方法
  - ▶ 反应结果排序、筛选和详情
  - ➤ 如何高效获取反应详情(Synthetic Methods)
- 分析相关信息的获取 (CAS Analytical Methods)





## CAS SciFinder检索--反应检索

- 反应检索方法
  - 结构式
- 常用获取方法
  - 已知物质: 由物质获取反应
  - 已知文献: 从文献中获取反应
  - = 精确结构反应检索
  - 亚结构反应检索




### Get reactions where the structure(s) are:

- Variable only at the specified positions
- Substructures of more complex structures






## 结构编辑器--绘制反应工具








## 反应检索--精确反应检索







### 反应检索结果集--排序








## 扩展反应检索--获取相似反应

选择相似反应的相似限制:

Broad: 仅反应中心相似

Miedum: 反应中心及附属原子和键


Narrow: 反应中心及扩展的原子和键








# 按照反应类型排序





## 反应检索结果集--筛选

### 获得特定物质做还原剂的反应







# 反应检索结果--Experimental Procedure

Single Step Hover over any structure for more options.



### Overview

### Steps/Stages

### Notes

1.1 R:H<sub>2</sub>, R:Cs<sub>2</sub>CO<sub>3</sub>, C:1610424-70-8, C:1034343-98-0 (oxide), S:PhMe, 2 h, 100°C, 1 atm solid-supported catalyst, palladium catalyst supported on graphene oxide prepared and used, reusable catalyst, Reactants: 1, Reagents: 2, Catalysts: 2, Solvents: 1, Steps: 1, Stages: 1, Most stages in any one step: 1

### References

Catalyst Enhancement and Recyclability by Immobilization of Metal Complexes onto Graphene Surface by Noncovalent Interactions

Quick View Other Sources By Sabater, Sara et al From ACS Catalysis, 4(6), 2038-2047; 2014

### **▼** Experimental Procedure




General/Typical Procedure: General Procedure for Nitroarene Reductions. Molecular hydrogen was added with a balloon filled with 1 atm of H<sub>2</sub> to a mixture of nitroarene (0.3 mmol). Cs.CO. (0.3 mmol). anisological integral dependent (0.2 mmol). of nitroarene (0.3 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.3 mmol), anisole as internal standard (0.3 mmol), and NHC-Pd-rGO (6 × 10<sup>-3</sup> mmol, based on metal) in toluene (5 mL). The system was then evacuated and backfilled with H<sub>2</sub> in cycles for three times before putting the reaction vessel in an oil bath at 100°C for 2h. Yields were determined by GC analyses using anisole (0.3 mmol) as internal standard. Products were identified according to spectroscopic data of the commercially available compounds. Entry: 4; Yield 100%.

### 不用阅读全文,直接获得包含实验过程的反应记录






### 反应检索结果--MethodsNow








### SciPlanner--设计合成反应路线








# SciPlanner--工作界面








# SciPlanner--工作界面








# SciPlanner--工作界面







# SciPlanner--设计拟合成的反应路线







# 反应检索小结

- 1. 反应检索方法汇总与区分
- 2. 反应绘制工具的灵活使用
- 3. 反应结果排序: Group by Transformation/Document
- 4. 反应结果的快速纵览及筛选,例如non-participating functional group;
- 5. 相似反应的获取获得更多启发
- 6. MethodsNow获取反应详情
- 7. SciPlanner工具助于自定义设计拟合成反应路线



## 大纲

- CAS及CAS SciFinder介绍
- 文献相关信息的获取策略
  - > 文献检索方法
  - ▶ 文献结果排序、筛选和详情
  - ▶ 如何高效阅读专利文献详情(CAS PatentPak)
- 物质相关信息的获取策略
  - ▶ 常见的物质检索方法
  - ▶ 物质结果排序、筛选和详情
- 反应相关信息的获取策略
  - ▶ 反应的获取方法
  - ▶ 反应结果排序、筛选和详情
  - ➤ 如何高效获取反应详情 (Synthetic Methods)
- 分析相关信息的获取 (CAS Analytical Methods)






### (www.methodsnow.com)

- Organic Compound Analysis: 天然产物分离分析,手性分离,活性药物成分及代谢产物分析…
- Organometallics / Inorganics: 地质分析,无机物分析,金属有机化合物分析
- Pharmacology / Toxicology: 成瘾药物检测,有毒物检测...
- Bioassays: 生物探针,生物标定细胞实验,生物标定药物实验,生物医学材料分析,生物分子/ 生物组织分离测定...
- Water Analysis: 阴阳离子分析,元素测定,痕量元素分析,废水分析,生物标记公共卫生分析…
- Historical Analysis / Dating: 考古分析,同位素分析
- Environmental Analysis: 土壤/空气/水分析,农药残留分析...
- Agricultural Applications / Analysis: 除草剂分析...
- Food Analysis: 脂肪酸分析, 脂肪酸酯分析, 蛋白质分析...
- Fuels / Geology / Biofuels: 生物燃料分析,油气分析,石油产品分析,煤炭加工...
- Miscellaneous: 化妆品分析,爆炸物分析,纳米材料分析...





### (www.methodsnow.com)




登陆www.methodsnow.com 输入SciFinder的账号密码






(www.methodsnow.com)








(www.methodsnow.com)








## 案例: 高效液相色谱法测定血液中罗红霉素的含量





### 结果显示





## 结果显示

Method Detail (2 of 5)

实验材料

### 文献信息

### Analysis of Roxithromycin in Blood plasma b

CAS MN: 1-101-CAS-67878

Method Category: Active Pharmaceutical Ingredient and Metabolite Analysis

Technique: Fluorescence; HPLC

Materials	Role
Roxithromycin	analyte
Blood plasma	matrix
Column, 125 x 4.6 mm i.d. LiChrospher RP-18e	materia

Source

Determination of roxithromycin in human plasma by HPLC with fluorescence and UV absorbance detection: Application to a pharmacokinetic study

Glowka, Franciszek K.; Karazniewicz-Lada, Marta

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2007), 852 (1-2), 669 - 673. Elsevier B.V.

CODEN: |CBAAI | ISSN: 15700232 | DOI: 10.1016/j.jchromb.2007.02.022

**Document Sources** 

#### Abstract ^

A selective HPLC method with fluorescence detection for the determination of roxithromycin (ROX) in human plasma was described. After solid-phase extraction (SPE), ROX and erythromycin (internal standard, I.S.) were derivatized by treatment with 9-fluorenylmethyl chloroformate (FMOC-CI). Optimal resolution of fluorescence derivatives of ROX and I.S. was obtained during one anal. run using reversed phase, C<sub>18</sub> column. The mobile phase was composed of potassium dihydrogenphosphate solution, pH 7.5 and acetonitrile. Fluorescence of the compounds was measured at the maximum excitation, 255 nm and emission, 313 nm, of ROX derivatives Validation parameters of the method were also established. After SPE, differences in recoveries of ROX and erythromycin from human plasma were observed The linear range of the standard curve of ROX in plasma was 0.5-10.0 mg/l. The validated method was successfully applied for pharmacokinetic studies of ROX after administration of a single tablet of ROX.

设备条件

### **Equipment Used**

Autosampler, G1313A

HPLC system, HP 1100, Hewlett-Packard, Waldbronn, Germany

SPE Bakerbond cartridges, C18

### Conditions

### Chromatographic

HPLC: mobile phase: 700 ml of acetonitrile  $\pm$  300 ml of a 0.05 mol/L column oven: at 40 °C, fluorescence detector excitation wavelength

### Instructions

material

#### Standards Preparation

- 1. Prepare stock solutions of roxithromycin (ROX) and erythromycin (I.S.) with 1  $_{\rm I}$
- 2. Prepare standard solutions: 5.0, 7.5,15.0, 20.0, 50.0, 75.0 and 100.0 mg/L of RO
- 3. Transfer the volume of 50 µL aliquots of the sample to a glass vial containing 0



S. n methanol

nlas na.

#### Solid phase extraction procedure

- 1. Process the resulting plasma samples containing: 0.5, 0.75, 1.5, 2.0, 5.0, 7.5 and 10.0 mg/l of ROX and 20.0 mg/l of I.S.according to the SPE.
- 2. Add the volume of 0.5 ml of a phosphate buffer, pH 7.5 (prepared as a mixture of 85.2 ml of 1/15 M Na<sub>2</sub>HPO<sub>4</sub> and 14.8 ml 1/15 M KH<sub>2</sub>PO<sub>4</sub>).
- 3. Transfer the samples into C18 SPE Bakerbond cartridges (J.T. Baker Mallinckrodt Deventer, Holland).
- 4. Wash the absorbed analytes with water and elute with methanol.
- 5. Evaporate the organic liquid to dryness at 40 °C.

#### Derivatization

- 1. Dissolve the residue in 200 µL aliquots of acetonitrile and transfer the sample to a glass reaction vial.
- 2. Add a 100 μL aliquots of a 2.5 mg/L 9-fluorenylmethyl chloroformate (FMOC-CI) in acetonitrile and 100 μL aliquots of a phosphate buffer, pH 7.5. 3. Incubate the sample at 40 °C for 40 min.
- 4. Inject an aliquot 100 μL after derivatization, onto the chromatographic system.

#### HP

- Prepare the mobile phase by mixing 700 mL of acetonitrile with 300 ml of a 0.05 mol/L solution of potassium dihydrogenphosphate in water, adjust to pH 7.5 with a 10% sodium hydroxide solution.
- 2. Determine ROX and I.S. in human plasma in a chromatograph model HP 1100 (Hewlett-Packard, Waldbronn, Germany).
- 3. Set at a flow rate of quaternary pump at 2 mL/min, a column oven at 40 °C and a fluorescence detector model HP 1046A and G13 21 A-1100, at an excitation wavelength (Ex) of 255 nm and emission wavelength (Em) of 315 nm.
- 4. Inject the samples (100 μL) using autosampler model G1313A.
- 5. Perform the separation on a 125 x 4.6 mm i.d. LiChrospher RP-18e column packed with 5 μm particles, with a guard column (LiChrospher RP-18e), both from Merck.





## 结果显示

					Ū		导出对比PDF文件	
	Expand All   Collapse A							
	1	⊗ 2			3			
Title	Analysis of Roxithromycin in Blood plasma by HPLC-tandem mass spectrometry		plasma by HPLC		Analysis of Roxithromycin in Blood plasma by High-performance liquid chromatography-mass spectrometry			
CAS Method Number	1-101-CAS-1241367		1-101-CAS-67878	1-101	I-CAS-10378			
Method Category	thod Category Active Pharmaceutical Ingredient and Active P		Active Pharmaceutical Ingredient and	Active	e Pharmaceutical Ingredient and			
Technique	Metabolite Analysis  HPLC-tandem mass speci	Other Materia	acetate; Heparin; C <sub>18</sub> analytical		Column, 125 x 4.6 mm i.d. LiChrospher RP-18e; SPE Bakerbor		Acetonitrile; Column (250 mm x 4.6 mm i.d., 5 μm)	
· ·	·	column (150 mm x 4.6 mm, 5 μm)			cartridges, C18			
Analyte	Roxithromycin; Ambroxo hydrochloride	Equipment Use	LC-MS/MS system, Thermo Finniga San Jose, CA; LC pump, Surveyor, Thermo Finnigan, San Jose, CA;	an,	HPLC system, HP 1100, Hewlett- Packard, Waldbronn, Germany; Autosampler, G1313A		HPLC, 1100, Agilent; Mass detector	
Matrix	Blood plasma		View All ✓					
		Condition	Instrument: Column: C <sub>18</sub> analytica column; column temperature: 30 ° mobile phase: mixture of methano View All ~	°C;	Chromatographic: HPLC : mobil phase : 700 ml of acetonitrile + 3 of a 0.05 mol/L solution of potas View All >	300 ml	Instrument: Detection- SIM mode. Chromatographic: Injection volume- 20 µL; mobile phase- (75:25, v/v) of View All ~	
		Sourc	Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol View All v		Determination of roxithromycin human plasma by HPLC with fluorescence and UV absorband View All V		Stochastic resonance is applied to quantitative analysis for weak chromatographic signal of View All V	
		Preparatio	Collection of plasma samples		Standards Preparation		Plasma samples	





## 浏览器选择建议

- Windows 7以上用户建议升级IE到10以上,不支持IE7、IE8
- Chrome和FireFox浏览器在所有系统上的表现都优于IE浏览器
- 不建议使用360浏览器检索SciFinder,会被自动拦截相关功能或插件




## 如何获取CAS SciFinder账号







## 如何获取CAS SciFinder账号



### 请注意:

- 1.必须输入真实姓名和学校邮箱。
- 2.用户名必须是唯一的,且包含 5-15 个字符。它可以只包含字母或字母组合、数字和/或以下特殊字符:
- · (破折号)
- \_ (下划线)
- . (句点)
- @ (表示"at"的符号)
- 3.密码必须包含 7-15 个字符,并且至少包含三种以下字符:
- 字母
- 混合的大小写字母
- 数字
- 非字母数字的字符(例如@、#、%、&、\*)

例: abc@123

4.从下拉列表中选择一个密码提示问题并给出答案。

单击 Register (注册)。

登录学校图书馆网站找到CAS SciFinder数据库说明页,按照提示进行注册





# 使用注意事项

- 一人注册一个帐号
- 字名注册,请提供真实姓名信息(中文名用汉语拼音全拼)
- 不得过量下载(以电子形式存储不超过5,000条记录)
- 不得账号分享
- 不得将账号用于非学术研究



# 常见问题



- 确认账号密码是否正确
- 如果账号密码正确,请填写问题报告后联系图书馆或china@acs-i.org





# 谢谢!





china@acs-i.org +86-10-62508026/27 www.cas.org 美国化学文摘社北京代表处



